Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fostamatinib - Rigel Pharmaceuticals

Drug Profile

Fostamatinib - Rigel Pharmaceuticals

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib disodium hexahydrate; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; Tavalisse

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Kissei Pharmaceutical; Rigel Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Phase III Autoimmune haemolytic anaemia
  • Phase I Graft-versus-host disease; Ovarian cancer
  • Research Waldenstrom's macroglobulinaemia
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; IgA nephropathy; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T-cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 15 Nov 2019 The CHMP issues positive opinion for the approval of fostamatinib for the treatment of Idiopathic thrombocytopenic purpura in European Union
  • 07 Nov 2019 Updated efficacy data from the phase II SOAR trial in Autoimmune haemolytic anaemia released by Rigel Pharmaceuticals
  • 05 Nov 2019 Rigel Pharmaceuticals announces intention to launch fostamatinib for Idiopathic thrombocytopenic purpura in Europe, Japan, and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top